Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate
Biotech Targets Triple-Negative Breast Cancer and Lymphoma
Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech. 
